NASDAQ · MCK
Healthcare · Medical - Distribution
$994.58
Up+$13.70 (+1.40%)
Updated Oct 31, 2026, 5:41 PM
SID Score
7.1/10
Composite research score
Smart Money
57/100
Neutral
Price performance · MCK
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
MCK closed at $994.58 after 21 trading sessions, up 10.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1,006.29 | $1,016.92 | $990.2959 | $994.58 | 763.21K |
| Oct 29, 2026 | $975.00 | $982.70 | $964.77 | $980.88 | 721.49K |
| Oct 28, 2026 | $955.95 | $970.925 | $954.05 | $960.56 | 764.14K |
| Oct 27, 2026 | $989.04 | $992.8225 | $966.49 | $967.02 | 587.07K |
| Oct 26, 2026 | $1,001.39 | $1,008.60 | $988.03 | $992.87 | 508.22K |
| Oct 23, 2026 | $1,010.32 | $1,012.495 | $997.02 | $1,000.77 | 628.97K |
| Oct 22, 2026 | $1,025.62 | $1,025.62 | $1,006.07 | $1,012.34 | 629.49K |
| Oct 21, 2026 | $1,020.93 | $1,030.00 | $1,005.42 | $1,015.50 | 772.09K |
| Oct 20, 2026 | $1,021.14 | $1,030.27 | $1,013.925 | $1,030.12 | 789.41K |
| Oct 19, 2026 | $995.72 | $1,012.58 | $977.8888 | $1,010.43 | 757.17K |
| Oct 16, 2026 | $1,012.20 | $1,014.99 | $999.27 | $1,004.84 | 621.36K |
| Oct 15, 2026 | $995.80 | $1,003.21 | $988.61 | $998.64 | 728.67K |
| Oct 14, 2026 | $968.07 | $979.82 | $965.045 | $976.57 | 769.08K |
| Oct 13, 2026 | $963.42 | $969.477 | $954.18 | $961.88 | 743.64K |
| Oct 12, 2026 | $949.95 | $956.24 | $936.7742 | $955.76 | 646.98K |
| Oct 9, 2026 | $927.56 | $943.97 | $925.00 | $938.84 | 482.91K |
| Oct 8, 2026 | $906.65 | $938.51 | $906.65 | $930.25 | 715.66K |
| Oct 7, 2026 | $924.21 | $933.99 | $908.49 | $910.33 | 794.46K |
| Oct 6, 2026 | $921.00 | $928.46 | $914.225 | $921.67 | 680.46K |
| Oct 5, 2026 | $905.22 | $922.46 | $900.72 | $915.45 | 697.63K |
| Oct 2, 2026 | $899.02 | $905.55 | $881.40 | $902.28 | 777.05K |
The latest Smart Investors Daily articles mentioning MCK.
Company
Market Activity
Research & News
MCK research
Company profile and research snapshot.
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2026 | Mizuho | Neutral | — |
| Oct 16, 2026 | UBS | Buy | — |
| Oct 7, 2026 | Leerink Partners | Outperform | — |
| Sep 14, 2026 | RBC Capital | Sector Perform | — |
| Aug 19, 2026 | Barclays | Overweight | — |
Generated Oct 31, 2026, 5:13 PM
McKesson Corporation gained 1.40% today as investors digest mixed signals around the company's Q2 earnings and valuation prospects. Recent analyst coverage suggests the healthcare distribution giant may be significantly undervalued, though questions persist about cash flow sustainability and near-term earnings trajectory.
Bottom line: McKesson appears caught between compelling valuation metrics suggesting 43% upside potential and legitimate concerns about earnings trajectory and cash flow quality. Investors should view Q2 earnings as a pivotal catalyst that could either validate the valuation discount or expose underlying operational challenges—making this a stock to watch closely through the earnings cycle.
Yahoo · Oct 30, 2026
Besides Wall Street's top-and-bottom-line estimates for McKesson (MCK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
Yahoo · Oct 29, 2026
McKesson's board has affirmed a regular quarterly dividend of US$0.94 per share, payable on 4 January 2027 to shareholders of record on 1 December 2026. This highlights ongoing cash returns alongside its broad healthcare distribution and services operations. The confirmed dividend coincides with an upcoming November 2026 earnings release, which focuses attention on how McKesson's cash generation supports both reinvestment in oncology and technology platforms as well as ongoing shareholder...
Yahoo · Oct 29, 2026
McKesson has delivered a powerful run over the past several years, and the share price sits near the top of its recent range. That kind of performance naturally raises a question for anyone looking at the stock today, which is whether the current valuation can be explained by the cash the business is expected to produce. Over the past 5 years, McKesson has returned about 339.6%, which puts serious weight on whether that share price climb is still in step with its underlying cash flows. The...
Yahoo · Oct 29, 2026
Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MCK.
